Augmenix, Inc. Announces SpaceOAR® Hydrogel is Now Available to Millions More Americans
SpaceOAR hydrogel, which is used to reduce common side effects that men experience after receiving prostate cancer radiotherapy, is now reimbursed by six out of seven Medicare Administrative Contractors (MACs), numerous Medicaid state programs, and, most recently, Aetna, Inc., which is the third largest commercial health insurance carrier in
“The coverage provided by a growing number of public and private insurance carriers is an acknowledgement of the significant clinical value of SpaceOAR hydrogel for their beneficiaries,” said
“We are pleased by the continued growth in insurance carrier coverage for the SpaceOAR procedure within a few months of the Category I CPT® Code (55874) becoming effective in January of this year,” said
About SpaceOAR Hydrogel
Radiation therapy in the treatment of prostate cancer can cause unintended radiation injury to adjacent healthy tissue (Organs At Risk). This injury can lead to a range of bowel, urinary, and sexual symptoms that can negatively affect patient health and quality of life during radiotherapy, and for years afterwards.
SpaceOAR hydrogel reduces the radiation dose delivered to the anterior rectum and reduces the risk of injury. In a clinical study, SpaceOAR hydrogel demonstrated a 99% procedural success rate, a 73.5% reduction in radiation dose to the rectum, and significantly less quality of life impact at 3 years. (1) Injected as a liquid into the space between the prostate and rectum, SpaceOAR hydrogel gently pushes the structures apart and then solidifies into a soft hydrogel, which maintains space for approximately three months during radiation therapy then liquefies and is completely absorbed by the body.
SpaceOAR Hydrogel, is cleared by the
See the Instructions for Use for complete information on potential risks, warnings, and precautions. For more information, visit SpaceOAR.com.
About
1. Hamstra D, et al. Continued Benefit to Rectal Separation for Prostate RT: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys; 2017 Volume 97, Issue 5, Pages 976–985.
Risks associated with the implantation of SpaceOAR hydrogel:
In addition to the risks associated with any medical procedure there are potential complications that may be associated with the use of the SpaceOAR System that include, but are not limited to: pain or discomfort associated with SpaceOAR hydrogel; needle penetration or injection of SpaceOAR hydrogel into the bladder, prostate, rectal wall, rectum or urethra; local inflammatory reactions; infection; injection of air, fluid or SpaceOAR hydrogel intravascularly; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding, constipation; and rectal urgency.
CPT is a registered trademark of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180413005544/en/
[email protected]
Source:
Strong Social Media Presence Critical Part of Success for Life Insurance Agents and Advisors, LIMRA/Life Happens Joint Report
Griffin-American Healthcare REIT IV Acquires Medical Office Building Near Madison, Wisconsin
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News